Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 5,000 shares of the company’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $181.45, for a total transaction of $907,250.00. Following the sale, the chief executive officer now directly owns 556,967 shares in the company, valued at approximately $101,061,662.15. The sale was disclosed in a document filed with the SEC, which is available at this link.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 1.56% during mid-day trading on Thursday, hitting $189.92. 662,496 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 52 week low of $120.38 and a 52 week high of $190.48. The stock has a 50-day moving average of $177. and a 200-day moving average of $169.. The company has a market cap of $11.52 billion and a price-to-earnings ratio of 204.22.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Tuesday, February 24th. The company reported $2.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.14. The company had revenue of $328.10 million for the quarter, compared to the consensus estimate of $319.74 million. On average, analysts predict that Jazz Pharmaceuticals plc – will post $9.77 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on JAZZ shares. Analysts at Deutsche Bank raised their price target on shares of Jazz Pharmaceuticals plc – from $185.00 to $186.00 and gave the company a “buy” rating in a research note on Monday. Analysts at Citigroup Inc. initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Friday, March 27th. They set a “buy” rating and a $195.00 price target on the stock. Analysts at TheStreet upgraded shares of Jazz Pharmaceuticals plc – from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd. Finally, analysts at Cantor Fitzgerald reiterated a “positive” rating and set a $175.00 price target on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, March 3rd. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $184.13.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (NASDAQ:JAZZ) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News Ratings for Jazz Pharmaceuticals plc – Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals plc – and related companies with Analyst Ratings Network’s FREE daily email newsletter.